A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving ...

Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the European Commission has granted marketing authorization to Constella ® (linaclotide 290mcg) for the ...

— Top-line Results Show Trial Met All Primary and Secondary Endpoints — CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE ...

Linaclotide is marketed by Allergan for the treatment of adults with moderate to severe IBS-C in Europe under the brand name CONSTELLA ®, and Ironwood’s partner Astellas received approval of ...

“As many as 34 million people in the U.S. i suffer from chronic constipation and many patients are not fully satisfied with currently available treatments. ii I am encouraged by the results from these ...

-- Agreement Also Returns to Allergan Rights to LINZESS® (linaclotide) in Mexico -- DUBLIN and CAMBRIDGE, Mass., Oct. 27, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical ...

August 30, 2012 — The US Food and Drug Administration (FDA) approved the drug linaclotide (Linzess, Ironwood Pharmaceuticals) today for the treatment of chronic idiopathic constipation and irritable ...

Cambridge, MA-based Ironwood ($IRWD) cleared a major milestone in its development this morning, winning an FDA approval for linaclotide and paving the way for its big ...

Please provide your email address to receive an email when new articles are posted on . Patients with constipation-predominant irritable bowel syndrome treated with a ...

Linaclotide Receives Positive CHMP Opinion for the Treatment of IBS-C -Linaclotide is a first-in-class therapeutic option for the symptomatic treatment of moderate to severe irritable bowel syndrome ...

A study, published in The American Journal of Gastroenterology, examined the efficacy and safety of linaclotide for patients with chronic idiopathic constipation. Philip Schoenfeld, MD, of ...